Gouvernance Scholar Rock Holding Corporation

Actions

SRRK

US80706P1030

Recherche biotechnologique et médicale

Temps réel estimé Cboe BZX 18:51:42 13/07/2026 Varia. 5j. Varia. 1 janv.
55,28 USD -2,53 % Graphique intraday de Scholar Rock Holding Corporation -0,15 % +25,48 %

Comité Exécutif: Scholar Rock Holding Corporation

Dirigeant
Fonctions occupéesDepuis
David Hallal

David Hallal

59 ans

Chief Executive Officer 27/04/2025
Mohammed Qatanani

Mohammed Qatanani

51 ans

Chief Tech/Sci/R&D Officer 01/09/2022
Lisa Wyman

Lisa Wyman

48 ans

Chief Tech/Sci/R&D Officer 29/01/2025
Jun Lin Ho

Jun Lin Ho

46 ans

General Counsel 01/03/2018
Corporate Secretary 01/03/2020
Robert Woods

Robert Woods

58 ans

Chief Operating Officer 27/04/2025
Jing Marantz

Jing Marantz

61 ans

Chief Tech/Sci/R&D Officer 09/11/2022
Caryn Parlavecchio

Caryn Parlavecchio

53 ans

Human Resources Officer 16/08/2021
Akshay Vaishnaw

Akshay Vaishnaw

63 ans

Chief Tech/Sci/R&D Officer 27/04/2025
Laura Ekas

Laura Ekas

Investor Relations Contact 01/09/2025
Vikas Sinha

Vikas Sinha

62 ans

Director of Finance/CFO 27/04/2025

Composition du Conseil d'Administration: Scholar Rock Holding Corporation

Administrateur
ComitésDepuis
David Hallal

David Hallal

59 ans

Compensation Committee 18/03/2025
Governance Committee Chair 01/07/2017
Nominating Committee Chair 01/07/2017
Governance Committee 18/03/2025
Nominating Committee 18/03/2025
Srini Akkaraju Akkaraju

Srini Akkaraju Akkaraju

58 ans

Governance Committee 01/04/2025
Nominating Committee 01/04/2025
Audit Committee 21/06/2024
Governance Committee Chair 18/03/2025
Nominating Committee Chair 18/03/2025
Kristina Burow

Kristina Burow

53 ans

Compensation Committee Chair
Governance Committee
Nominating Committee
Joshua Reed

Joshua Reed

53 ans

Governance Committee 01/04/2025
Nominating Committee 01/04/2025
Audit Committee Chair 18/03/2021
Jeffrey Flier

Jeffrey Flier

78 ans

Governance Committee Chair 01/04/2025
Nominating Committee Chair 01/04/2025
Katie Peng

Katie Peng

55 ans

Audit Committee 27/06/2024
Compensation Committee 01/04/2025
Richard Brudnick

Richard Brudnick

68 ans

Audit Committee Chair
Audit Committee 06/04/2023
Michael Gilman

Michael Gilman

70 ans

Compensation Committee 18/03/2021
Akshay Vaishnaw

Akshay Vaishnaw

63 ans

Director/Board Member 21/05/2019

Anciens Dirigeants et Administrateurs: Scholar Rock Holding Corporation

Insider
Fonctions occupées
DepuisJusqu'au
Rushmie Nofsinger
Rushmie Nofsinger
Investor Relations Contact 01/12/2021 01/09/2025
Public Communications Contact 01/12/2021 -
Tracey Sacco
Tracey Sacco
Corporate Officer/Principal 06/02/2023 01/06/2025
Beth Shafer
Beth Shafer
Corporate Officer/Principal 04/09/2024 01/05/2025
Jay Backstrom
Jay Backstrom
Director/Board Member 20/10/2022 27/04/2025
Chief Executive Officer 20/09/2022 27/04/2025
President 20/10/2022 27/04/2025
Edward Myles
Edward Myles
Comptroller/Controller/Auditor - 15/03/2025
Director/Board Member 19/11/2018 16/07/2020
Chief Operating Officer 16/07/2020 15/03/2025
Director of Finance/CFO 16/07/2020 15/03/2025
Independent Dir/Board Member 19/11/2018 16/07/2020
Amir Nashat
Amir Nashat
Director/Board Member 01/10/2012 27/06/2024
Independent Dir/Board Member 01/10/2012 27/06/2024
George G Nomikos
George G Nomikos
Chief Tech/Sci/R&D Officer 05/09/2019 02/11/2022
Gregory Carven
Gregory Carven
Chief Tech/Sci/R&D Officer 04/02/2021 01/10/2022
Corporate Officer/Principal 01/01/2014 04/02/2021
Yung H. Chyung
Yung H. Chyung
Chief Tech/Sci/R&D Officer 01/02/2016 30/06/2022
Catherine Hu
Catherine Hu
Investor Relations Contact 01/03/2018 01/10/2021
Public Communications Contact 01/03/2018 01/10/2021
Tony Kingsley
Tony Kingsley
Director/Board Member 20/05/2020 29/07/2021
Chief Executive Officer 01/08/2020 29/07/2021
Independent Dir/Board Member 20/05/2020 01/08/2020
President 01/08/2020 29/07/2021
Dodzie Sogah
Dodzie Sogah
Corporate Officer/Principal 01/03/2016 01/03/2021
Lisa Amaya Price
Lisa Amaya Price
Human Resources Officer 11/04/2019 01/10/2020
Nagesh Mahanthappa
Nagesh Mahanthappa
Director/Board Member 01/10/2012 01/08/2020
Chief Executive Officer 01/10/2012 01/08/2020
President 01/10/2012 01/08/2020
Director/Board Member 30/07/2021 20/10/2022
Chief Executive Officer 30/07/2021 20/10/2022
President 30/07/2021 20/10/2022
Erin Moore
Erin Moore
Comptroller/Controller/Auditor 01/10/2018 01/07/2020
Corporate Officer/Principal 01/10/2018 01/07/2020
Comptroller/Controller/Auditor 21/03/2025 27/04/2025
Director of Finance/CFO 21/03/2025 27/04/2025
Heather Faulds
Heather Faulds
General Counsel 01/09/2017 01/06/2020
Rhonda Chicko
Rhonda Chicko
Comptroller/Controller/Auditor 01/04/2018 30/09/2019
Director of Finance/CFO 01/04/2018 30/09/2019
Timothy Springer
Timothy Springer
Director/Board Member 01/10/2012 21/05/2019
Founder 01/10/2012 21/05/2019
Independent Dir/Board Member 01/10/2012 21/05/2019
Elan Ezickson
Elan Ezickson
Chief Operating Officer 25/04/2017 31/12/2018
Alan J. Buckler
Alan J. Buckler
Chief Tech/Sci/R&D Officer 01/11/2016 -
Leonard I. Zon
Leonard I. Zon
Founder 01/10/2012 -
Nily Osman
Nily Osman
Chief Tech/Sci/R&D Officer - -

Distribution de l'Âge des Dirigeants

Parité Homme Femme

Homme12
Femme7

Dont comité exécutif

Homme7
Femme3

Dont Administrateurs

Homme7
Femme2

Révisions

Recommandations analystes
-
Évolution recommandations analystes 1 an
-
Évolution recommandations analystes 4 mois
-
Objectif analystes
-
Évolution objectif analystes 1 an
-
Évolution objectif analystes 4 mois
-
ESG MSCI

ESG MSCI

Environnement
Social
Gouvernance
Polémique
Controverses Ethiques
Non
Controverses sur les droits de l'Homme
Non
Controverses Subventions fiscales
Non
Conforme à la finance Islamique
-
Logo Scholar Rock Holding Corporation
Scholar Rock Holding Corporation est une société biopharmaceutique. La société se consacre à l'amélioration de la qualité de vie des enfants et des adultes atteints d'amyotrophie spinale (SMA) ainsi que d'autres maladies neuromusculaires rares, graves et invalidantes. Son portefeuille de produits candidats comprend l'apitegromab, une formulation sous-cutanée de l'apitegromab, et le SRK-439. L'apitegromab est un anticorps monoclonal entièrement humain, administré par voie intraveineuse, actuellement à l'étude, conçu pour inhiber l'activation de la myostatine en se liant de manière sélective aux formes pro- et latentes de la myostatine dans le muscle squelettique. Le SRK-439 est un anticorps anti-myostatine pro/latente entièrement humain, à usage expérimental et administré par voie sous-cutanée, qui présente un fort pouvoir inhibiteur tout en conservant une sélectivité vis-à-vis de la myostatine. Son portefeuille de produits en phase précoce comprend d’autres programmes destinés au traitement de patients atteints de maladies neuromusculaires rares, graves et invalidantes.
Employés
289

Départs de Personnes Clées

Jay Backstrom
-
Jay Backstrom

Chief Executive Officer

20/09/2022 27/04/2025

Tony Kingsley
-
Tony Kingsley

Chief Executive Officer

01/08/2020 29/07/2021

Nagesh Mahanthappa
-
Nagesh Mahanthappa

Chief Executive Officer

01/10/2012 01/08/2020

🔇